Table 2 Analytical studies of acylcarnitines in humans with and without T2D
From: Role of carnitine and its derivatives in the development and management of type 2 diabetes
Participant characteristics | Sample type | Affected acylcarnitine species | Affected glycemic and lipid parameters | Ref |
|---|---|---|---|---|
Twelve lean volunteers (3M/9F), age:47 ± 7, BMI:23.9 ± 1.8 14 obese nondiabetic v. (3M/11F), age:43 ± 7, BMI:34.3 ± 3.1 10 T2D patients (5M/5F), age:45±10, BMI:34.2±2.5 | Plasma | T2D vs control: FC↑, C3↑, C4↑, C5↑, C6↑, C10:1↑ (LCAC) C14:1↑, C16↑, C18↑, C18:1↑ (OH) C4OH↑, C5OH↑, C6OH↑, C14OH↑, C16OH↑ | FPG↑, HbA1c↑ | |
Eighteen DM patient (6M/12F), 14 controls (6M/8F) | Urine | FC↓, MCAC↑, (C7↑, C8↑, C12↑C14↑) LCAC↑ (C16↑) | n.m. | |
Forty four T2D patient (44F), aged 19–87y 12 nondiabetic control (12F), aged 21–69y | Plama | AC↑, AC/FC↑, C2↑, (MCAC) C6↑, C8↑, C10↑, (LCAC)C14↑, C18:1↑ C3↓ | FPG↑, HbA1c↑ | |
Seventy four obese volunteers (22M/52F), aged 46–60 y, BMI:36.6 67 lean volunteers (29M/38F), aged 38–60y, BMI:23.2 | Serum | C3↑, C5↑, C6↑, C8:1↑ | FFA↑, TG↑, HDL-C↓, pyruvate↑, lactate↑ | |
Twenty patients with normal glucose tolerance (9M/11F), mean age: 48y 20 pre-DM patients (11M/9F), mean age: 51y 21 newly diagnosed T2D patients (8M/13F), mean age: 49y | Serum | T2D vs control: C16↑, C16-OH↑, C20↑, C22↑, C24↑ | FPG↑, HbA1c↑, FINS↑ IR↑, TC↑ | |
Forty nine T1D patients (26M/23F), aged 19–64y, BMI: 25.7 38 T2D patients (20M/18F), aged 37–57y, BMI: 29.9 38 MetS patients (19M/19F), aged 34–70y, BMI: 33.8 40 healthy controls (20M/20F), aged 28–71y, BMI: 23.1 | Serum | T2D vs control: C2↑, C3↑, C4↑, C5↑, C10:1↓, C12↓, C18:2↓, SCAC↑, MCAC↓, LCAC ↔ | n.m. |
